{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:13:38Z","timestamp":1787912018637,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["269855"],"award-info":[{"award-number":["269855"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["269855"],"award-info":[{"award-number":["269855"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients on opioid agonist therapy (OAT) are common and have pros and cons. The objectives of the current study are to define the dispensation rates of these potentially addictive drugs, and whether the number and the mean daily doses of dispensed OAT opioids and discontinuing OAT, are associated with being dispensed benzodiazepines, z-hypnotics and gabapentinoids among patients on OAT in Norway in the period 2013 to 2017.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Information about all dispensed opioids, benzodiazepines, z-hypnotics and gabapentinoids were recorded from the Norwegian Prescription Database (NorPD). A total of 10,371 OAT patients were included in the study period. The dispensation rates were defined as the number of patients who were dispensed at least one of the potentially addictive drugs divided among the number of patients who have dispensed an OAT opioid per calendar year. Mean daily doses were calculated, and for benzodiazepines and z-hypnotics, stated in diazepam equivalents. The association between dispensed potentially addictive drugs, and the number and the type of dispensed OAT opioids were calculated by using logistic regression models.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Half of the OAT patients received at least one dispensation of a benzodiazepine or z-hypnotic, and 11% were dispensed at least a gabapentinoid in 2017. For dispensed benzodiazepines or z-hypnotics, the mean daily dose was reduced from 21\u2009mg (95% confidence interval (CI): 20\u201323) diazepam equivalents in 2013 to 17\u2009mg (95% CI: 16\u201317) in 2017. The mean daily dose of pregabalin increased from 365\u2009mg (95% CI: 309\u2013421) in 2013 to 386\u2009mg (95% CI: 349\u2013423) in 2017. Being dispensed a gabapentinoid (adjusted odds ratio (aOR)\u2009=\u20092.5, 95% CI: 2.1\u20133.0) or a non-OAT opioid (aOR\u2009=\u20093.0, 95% CI: 2.6\u20133.5) was associated with being dispensed a benzodiazepine or z-hypnotic. Discontinuing OAT did not affect the number of dispensations and the doses of potentially addictive drugs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The dispensation rates of potentially addictive drugs are high in the OAT population. Treatment indications, as well as requirements for prescription authority, need to be debated and made explicit. Randomized controlled trials evaluating the benefits and risks of such co-prescription are required.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12913-020-05195-5","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T18:03:33Z","timestamp":1587837813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017"],"prefix":"10.1186","volume":"20","author":[{"given":"J\u00f8rn Henrik","family":"Vold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Skurtveit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Aas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Chalabianloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia Synn\u00f8ve","family":"Kloster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell Arne","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Thore","family":"Fadnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"key":"5195_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","volume":"174","author":"T Abrahamsson","year":"2017","unstructured":"Abrahamsson T, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-a nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58\u201364.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"5195_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/0269881116675508","volume":"31","author":"A Bakker","year":"2017","unstructured":"Bakker A, Streel E. Benzodiazepine maintenance in opiate substitution treatment: good or bad? A retrospective primary care case-note review. J Psychopharmacol. 2017;31(1):62\u20136.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"5195_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/10550880802122620","volume":"27","author":"B Brands","year":"2008","unstructured":"Brands B, Blake J, Marsh DC, Sproule B, Jeyapalan R, Li S. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis. 2008;27(3):37\u201348.","journal-title":"J Addict Dis"},{"issue":"4","key":"5195_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1360-0443.1994.tb00909.x","volume":"89","author":"S Darke","year":"1994","unstructured":"Darke S. Benzodiazepine use among injecting drug users: problems and implications. Addiction. 1994;89(4):379\u201382.","journal-title":"Addiction"},{"key":"5195_CR5","first-page":"1","volume":"336","author":"W Loxley","year":"2007","unstructured":"Loxley W. Benozdiazepine use and harms among police detainees in Australia. Aust Inst Criminol. 2007;336:1.","journal-title":"Aust Inst Criminol"},{"issue":"2","key":"5195_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/pds.1694","volume":"18","author":"F Charlson","year":"2009","unstructured":"Charlson F, Degenhardt L, McLaren J, Hall W, Lynskey M. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiol Drug Saf. 2009;18(2):93\u2013103.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5195_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","volume":"200","author":"VR Votaw","year":"2019","unstructured":"Votaw VR, Geyer R, Rieselback R, McHugh RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;200:95\u2013114.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"5195_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","volume":"30","author":"S Chiappini","year":"2016","unstructured":"Chiappini S, Schifano F. A decade of Gabapentinoid misuse: an analysis of the European medicines Agency\u2019s \u2018Suspected adverse drug Reactions\u2019 database. CNS Drugs. 2016;30(7):647\u201354.","journal-title":"CNS Drugs"},{"issue":"11","key":"5195_CR9","doi-asserted-by":"publisher","first-page":"e1002965","DOI":"10.1371\/journal.pmed.1002965","volume":"16","author":"J Macleod","year":"2019","unstructured":"Macleod J, Steer C, Tilling K, Cornish R, Marsden J, Millar T, Strang J, Hickman M. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: observational study based on the UK clinical practice research Datalink and Office for National Statistics death records. PLoS Med. 2019;16(11):e1002965.","journal-title":"PLoS Med"},{"key":"5195_CR10","volume-title":"European Monitoring Centre for Drugs and Drug Addiction","author":"Addiction EMCfDaD","year":"2017","unstructured":"Addiction EMCfDaD. Health and social responses to drug problems - A European Guide. In: European Monitoring Centre for Drugs and Drug Addiction; 2017. http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/6343\/TI_PUBPDF_TD0117699ENN_PDFWEB_20171009153649.pdf."},{"key":"5195_CR11","unstructured":"Sweden Country Drug Report 2018. In.\nhttp:\/\/www.emcdda.europa.eu\/system\/files\/publications\/11321\/sweden-cdr-2018-with-numbers.pdf: European Monitoring Centre for Drugs and Drug Addiction; 2018."},{"key":"5195_CR12","unstructured":"Sweden Country Drug Report 2019. In.\nhttp:\/\/www.emcdda.europa.eu\/system\/files\/publications\/11354\/sweden-cdr-2019_0.pdf: European Monitoring Centre for Drugs and Drug Addiction; 2019."},{"key":"5195_CR13","unstructured":"The misuse of benzodiazepines among high-risk opioid users in Europe. In.\nhttp:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2733\/Misuse%20of%20benzos_POD2015.pdf: European Monitoring Centre for Drugs and Drug Addiction; 2018."},{"key":"5195_CR14","unstructured":"The Norwegian guidelines for opioid agonist therapy (norsk: Nasjonal retningslinje for legemiddelassistert rehabailitering ved opioidavhengighet). In.\nhttps:\/\/helsedirektoratet.no\/Lists\/Publikasjoner\/Attachments\/100\/IS-1701-Legemiddelassistert-rehabilitering-ved-opioidavhengighet.pdf: The Norwegian Directorate of Health; 2010."},{"key":"#cr-split#-5195_CR15.1","unstructured":"Waal H, Bussesund K, Clausen T, Lillevold P, Skeie I: Statusrapport 2017, LAR 20 \u00e5r. Status, vurderinger og perspektiver. In."},{"key":"#cr-split#-5195_CR15.2","unstructured":"https:\/\/www.med.uio.no\/klinmed\/forskning\/sentre\/seraf\/publikasjoner\/rapporter\/2018\/seraf-rapport-nr-3-2018-statusrapport-2017.pdf: Norwegian Centre for Addiction Research (SERAF); 2017."},{"issue":"4","key":"5195_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","volume":"77","author":"KE Evoy","year":"2017","unstructured":"Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of Pregabalin and gabapentin. Drugs. 2017;77(4):403\u201326.","journal-title":"Drugs"},{"issue":"4","key":"5195_CR17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/01.pra.0000358318.73684.df","volume":"15","author":"SP Kruszewski","year":"2009","unstructured":"Kruszewski SP, Paczynski RP, Kahn DA. Gabapentin-induced delirium and dependence. J Psychiatr Pract. 2009;15(4):314\u20139.","journal-title":"J Psychiatr Pract"},{"issue":"6","key":"5195_CR18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00228-012-1464-6","volume":"69","author":"M Gahr","year":"2013","unstructured":"Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69(6):1335\u201342.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"5195_CR19","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2146\/ajhp090313","volume":"67","author":"TR Hellwig","year":"2010","unstructured":"Hellwig TR, Hammerquist R, Termaat J. Withdrawal symptoms after gabapentin discontinuation. Am J Health-System Pharm. 2010;67(11):910\u20132.","journal-title":"Am J Health-System Pharm"},{"issue":"10","key":"5195_CR20","first-page":"e3425","volume":"10","author":"S Naveed","year":"2018","unstructured":"Naveed S, Faquih AE, Chaudhary AMD. Pregabalin-associated discontinuation symptoms: a case report. Cureus. 2018;10(10):e3425.","journal-title":"Cureus"},{"key":"5195_CR21","unstructured":"Definition and general considerations. In: https:\/\/wwww.hoccno\/ddd\/definition_and_general_considera\/#Definition\n. WHO Collaborating Centre for Drug Statistics; 2019."},{"key":"5195_CR22","unstructured":"The Norwegian guidelines for addictive drugs (Norsk: Nasjonal faglig veileder vanedannende legemidler. In.\nhttps:\/\/helsedirektoratet.no\/retningslinjer\/vanedannende-legemidler\/seksjon?Tittel=oversikt-og-ekvipotens-for-5789: The Norwegian Directorate of Health; 2019."},{"issue":"2\u20133","key":"5195_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.drugalcdep.2007.03.008","volume":"90","author":"JG Bramness","year":"2007","unstructured":"Bramness JG, Kornor H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend. 2007;90(2\u20133):203\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"5195_CR24","unstructured":"The Norwegian Prescription Database (NorPD) In.\nhttp:\/\/www.norpd.no\/: Norwegian Institute of Public Health (NIPH), the Norwegian Institute of Public Health; 2019."},{"issue":"8","key":"5195_CR25","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/add.14188","volume":"113","author":"M Hickman","year":"2018","unstructured":"Hickman M, Steer C, Tilling K, Lim AG, Marsden J, Millar T, Strang J, Telfer M, Vickerman P, Macleod J. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. Addiction. 2018;113(8):1461\u201376.","journal-title":"Addiction"},{"key":"5195_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.drugalcdep.2018.08.038","volume":"193","author":"C Higgins","year":"2018","unstructured":"Higgins C, Smith BH, Matthews K. Substance misuse in patients who have comorbid chronic pain in a clinical population receiving methadone maintenance therapy for the treatment of opioid dependence. Drug Alcohol Depend. 2018;193:131\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"5195_CR27","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/pme.12430","volume":"15","author":"KE Dunn","year":"2014","unstructured":"Dunn KE, Brooner RK, Clark MR. Severity and interference of chronic pain in methadone-maintained outpatients. Pain Med. 2014;15(9):1540\u20138.","journal-title":"Pain Med"},{"issue":"2","key":"5195_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-152-2-201001190-00006","volume":"152","author":"KM Dunn","year":"2010","unstructured":"Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85\u201392.","journal-title":"Ann Intern Med"},{"issue":"3","key":"5195_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1521-0391.2012.00327.x","volume":"22","author":"DT Barry","year":"2013","unstructured":"Barry DT, Savant JD, Beitel M, Cutter CJ, Moore BA, Schottenfeld RS, Fiellin DA. Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study. Am J Addict. 2013;22(3):212\u20137.","journal-title":"Am J Addict"},{"key":"5195_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.drugalcdep.2016.06.024","volume":"166","author":"JI Tsui","year":"2016","unstructured":"Tsui JI, Lira MC, Cheng DM, Winter MR, Alford DP, Liebschutz JM, Edwards RR, Samet JH. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy. Drug Alcohol Depend. 2016;166:26\u201331.","journal-title":"Drug Alcohol Depend"},{"key":"5195_CR31","first-page":"59","volume":"9","author":"BB Dennis","year":"2015","unstructured":"Dennis BB, Bawor M, Naji L, Chan CK, Varenbut J, Paul J, Varenbut M, Daiter J, Plater C, Pare G, et al. Impact of chronic pain on treatment prognosis for patients with opioid use disorder: a systematic review and meta-analysis. Subst Abus. 2015;9:59\u201380.","journal-title":"Subst Abus"},{"key":"5195_CR32","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. Bmj. 2017;357:j1550.","journal-title":"Bmj"},{"key":"5195_CR33","first-page":"Cd004145","volume":"8","author":"L Gowing","year":"2011","unstructured":"Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;8:Cd004145.","journal-title":"Cochrane Database Syst Rev"},{"key":"5195_CR34","unstructured":"Methadone and buprenorphine for the management of opioid dependence. In.\nhttps:\/\/www.nice.org.uk\/guidance\/ta114\/resources\/methadone-and-buprenorphine-for-the-management-of-opioid-dependence-pdf-82598072878789. National Institute for Health and Clinical Excellence (NICE); 2007, updated 2016."},{"key":"5195_CR35","unstructured":"Opioid substitution therapy for patients with opioid dependence (Swedish: L\u00e4kemedelassisterad behandling vid opiatberoende - slutsatser och f\u00f6rslag), In. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/ovrigt\/2015-3-35.pdf: The Swedish National Board of Health Welfare (Swedish: Socialstyrelsen); 2015."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-020-05195-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-020-05195-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-020-05195-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T23:43:44Z","timestamp":1619307824000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-020-05195-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5195"],"URL":"https:\/\/doi.org\/10.1186\/s12913-020-05195-5","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"29 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Regional Committee for Medical and Health Research Ethics, REC vest, Norway, has approved the use of registry data for the study (approval number 2018\/939\/REK Vest, June 19, 2018). No informed consent from the patients was necessary.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"352"}}